Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALERT: Alternating Eribulin and Hormonal Therapy in ER+ Breast Cancer
NCT02681523Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Oct 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in breast cancer, sponsored by Imperial College London. Primary endpoint: Progression Free Survival at 9 months. Started Oct 2015; status: terminated.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02681523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681523.